Erbitux
Merck scores expanded NICE recommendation in head, neck and oral cancer
August 8, 2017Manufacturing and Production, Sales and Marketing Erbitux, Merck, NICE, biotech, cetuximah, drugs, life sciences, pharma, pharmaceuticals
Merck has announced its approval of NICE’s decision to expand its recommendation of Erbitux (cetuximab) to include its use as …
BMS names Fouad Namouni as new oncology development head
July 26, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bristol-Myers Squibb, Erbitux, Fouad Namouni, Taxol, Yervoy, appointment, opdivo
Bristol-Myers Squibb has announced the appointment of Fouad Namouni to the position of oncology development head, effective July 25, 2016. …
Merck’s colorectal cancer drug meets primary endpoint in Phase III study
April 25, 2016Research and Development, Sales and Marketing Erbitux, Merck, Serono, cancer drugs, colorectal cancer, increased survival, oncology, phase 3, phase III
Merck (FWB: MRK) has announced that its Phase III clinical trial of Erbitux, in combination with Folfox, met its primary …
Merck and Biocartis partner on new biomarker test for colorectal cancer
January 7, 2016Research and Development BRAF mutations, Diagnostics, Erbitux, Merck, RAS metations, diagnostic tests, metastic colorectal cancer
Merck has signed a collaboration agreement with diagnostics company Biocartis for the development and commercialisation of a new test for …
Merck’s Erbitux approved for NHS Wales
January 5, 2016Manufacturing and Production, Sales and Marketing Erbitux, Merck, cetuximab, colorectal cancer, metastatic colorectal cancer
The All Wales Medicines Strategy Group has recommended Merck’s Erbitux in combination with chemotherapy for restricted use in the NHS …
Merck KGaA’s sales climb but key drugs fall
May 19, 2015Sales and Marketing Erbitux, Merck, Merck KGaA, Q1, Rebif
Merck KGaA encountered an uneven start to 2015, with robust sales in the first quarter offset by declines in key …
Merck and Galderma breach ABPI code
December 8, 2014Medical Communications, Sales and Marketing ABPI, Erbitux, Galderma, PMCPA, merch
Merck Serono and Galderma will be named in advertisements as guilty of the most serious breach of the ABPI Code …
Merck KGaA declines in Q2
August 7, 2013Sales and Marketing Erbitux, Merck KGaA, Q2, Serono
Sales of cancer drug Erbitux dropped as Merck Serono’s revenues for the second quarter of 2013 dipped year-on-year, the firm …
Merck Serono censured over calls
June 25, 2013Medical Communications, Sales and Marketing ABPI, Erbitux, Merck Serono, PMCPA
A Merck Serono medical representative has been accused of ‘harassing’ an anonymous health professional by requesting a meeting every month …
Sanofi’s Zaltrap data published
October 8, 2012Research and Development, Sales and Marketing Erbitux, Sanofi, Stivarga, Zaltrap, avastin
Detailed data from the Phase III trial of Sanofi’s newly-licenced anti-VEGF cancer drug Zaltrap, co-marketed with Regeneron, has been published. …
Erbitux fails in gastric cancer trial
July 6, 2012Research and Development, Sales and Marketing Erbitux, Merck Serono, Roche, failure, gastric cancer
Merck’s Erbitux has failed to increase survival in patients with gastric cancer, representing a blow to the firm’s ambition to …
Merck KGaA’s colon cancer drug fails trial
May 16, 2012Research and Development, Sales and Marketing Erbitux, Merck KGaA, Merck Serono, colon cancer
Merck KGaA has suffered a setback with key brand Erbitux as the colerectal cancer drug failed in a late-stage trial. …
FDA grants priority review for Sanofi cancer drug
April 5, 2012Research and Development, Sales and Marketing Erbitux, FDA, Regeneron, Sanofi, Zaltrap, colorectal cancer, prostate cancer
The FDA has granted Sanofi and partner Regeneron priority review for their colorectal cancer drug Zaltrap. Zaltrap (aflibercept) is seeking a …
NICE rejects three bowel cancer drugs
September 5, 2011Sales and Marketing Erbitux, NICE, Vectibix, avastin, colorectal cancer
NICE says three treatments – Roche’s Avastin, Merck KgAa’s Erbitux and Amgen’s Vectibix – are all not cost effective in …
Latest content
FibroFind appoints Lee Borthwick as CEO
